1Aoki KR. Pharmacology and immunolgy of botulinurn toxin serotypes. J Neurol,2001;248:3-10.
2Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: The clinical usefulness of botulinurn toxin A in treating neurologic disorders. Neurology, 1990; 40:1332-6.
3Cakrnur R, Ozturk V, Uzunel F, et al. Comparison of preseptal and pretarsal injections of botulimun toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol, 2002 ; 249:64-8.
4Andres O, Ceballos-Baumann. Evidence-based medicine in botulinum toxin therapy for cervical dystonia. J Neurol, 2001;248:14-20.
5Dressier D. Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therpy. Eur J Neurol, 2000; 7(6) :713-8.
6Wissel J, Muller J, Heinen F, et al. Safety and tolerance of single-dose botulinum toxin type A treatment in 204 patients with spastieity and localized associated symptoms. Wien Kiln Wochenschr, 1999; 111(24) : 1051.
7Kirschner J, Berweck S, Mall V, et al. Botulinum toxin treatment in cerebral palsy: evidence for a new treatment option. J Neurol,2001;248:28-30.
8Kwak CH, Hanna PA, Jankovic J. Botrlinum toxin in the treatment of tics. Arch Neurol,2000;57:1190-3.
9Tintner R, Jankovic J. Focal dystonia: the role of botulinum toxin. Curr Neurol Neurosci Rep,2001 ; 1 (4) : 337-45.
